RAVULIZUMAB

ravulizumab 1.1 g/11 mL injection, 11 mL vial
Manner of administration:Injection
Private
S100 HSD Private
Authority Required

Restriction

Indication: Bridging therapy for generalised myasthenia gravis (gMG)
Treatment phase: Non-loading/maintenance doses

Restriction

Indication: Treatment refractory generalised myasthenia gravis (gMG)
Treatment phase: Initial treatment - Treatment refractory gMG patients (Non-loading/maintenance doses)

Restriction

Indication: Treatment refractory generalised myasthenia gravis (gMG)
Treatment phase: Continuing treatment - Treatment refractory gMG patients

Restriction

Indication: Treatment refractory generalised myasthenia gravis (gMG)
Treatment phase: Transitioning from non-PBS to PBS-subsidised treatment - Grandfathering treatment
Quantities & Cost
Max qty packs Max qty units # of repeats DPMQ Max safety net General Patient Charge
Max qty packs: 1 Max qty units: 1 # of repeats: 2 DPMQ: $24,153.99 Max safety net: $25.00 General Patient Charge: $25.00
Available brands
Ultomiris